Speedy Summary:
- A new “molecular shield” approach coudl offer relief too hay fever sufferers by blocking pollen in the nasal lining without causing typical side effects like drowsiness.
- Hay fever triggers an allergic reaction when pollen binds to IgE antibodies, causing inflammation and symptoms like sneezing and itchiness. Current treatments, such as antihistamines and steroids, are often ineffective or cause adverse effects.
- researchers led by Kaissar tabynov applied a non-allergic antibody extracted from mice that blocks mugwort pollen allergens from attaching to IgE antibodies. In tests on mice, those treated with this antibody showed significantly reduced irritation compared to untreated ones (nose rubbing reduced from 92 times to 12 times).
- The study demonstrated both local nasal tissue protection and systemic anti-inflammatory effects after imaging nose tissue samples. Though, researchers did not measure potential human-side effects but anticipate minimal risk as the treatment targets the site of allergen entry directly.
- Human trials could begin within 2-3 years once the antibody is adapted for safety in humans, possibly using it for different types of pollen allergies via customized nasal sprays.
!campaign=RSS%7CNSNS&utmsource=NSNS&utmmedium=RSS&utm_content=home”>Original Article